ClinicalTrials.gg
RecruitingNCT07282574MintakaUpdated Oct 7, 2026

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

A Phase 2 interventional study of RO7268489 and Ocrelizumab in Progressive Multiple Sclerosis, sponsored by Hoffmann-La Roche. Recruiting at 114 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 7, 2026First site in BrazilEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche — 2 open to participants now, 8 under way, 4 of them phase 3. Multiple Sclerosis, Chronic Progressive · Hoffmann-La Roche.

Planned enrollment
7th of 12
360 · median 400
Started
2026
with 1 other
Phase 2
Only one
of the 12
Registered
9th of 12
by date

Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 2, and was the 9th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

03

Conditions studied

  • Progressive Multiple Sclerosis
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PMS, in accordance with the revised 2017 McDonald criteria
  • Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive
  • Documented evidence of disability progression independent of relapse activity over the 2 years before the screening visit

Exclusion criteria

Exclusion Criteria:

  • MS relapse during the 6 months preceding the randomization date
  • Lack of peripheral venous access
  • History of alcohol or other drug abuse (substance use disorder) based on Diagnostic and Statistical Manual for Mental Disorders, fifth edition () criteria, within 5 years prior to screening
  • Inability to complete a magnetic resonance imaging (MRI)
  • to ocrelizumab mandatory pre-medications
  • Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    RO7268489 Dose 1 + Ocrelizumab

    Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.

    Drug: RO7268489 · Drug: Ocrelizumab

  • Experimental
    RO7268489 Dose 2 + Ocrelizumab

    Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.

    Drug: RO7268489 · Drug: Ocrelizumab

  • Experimental
    RO7268489 Dose 3 + Ocrelizumab

    Participants will receive RO7268489 along with ocrelizumab as per the pre-defined regimen.

    Drug: RO7268489 · Drug: Ocrelizumab

  • Placebo comparator
    Placebo + Ocrelizumab

    Participants will receive RO7268489 matching placebo along with ocrelizumab as per the pre-defined regimen.

    Drug: Ocrelizumab · Drug: Placebo

Interventions

  • DrugRO7268489

    RO7268489 will be administered per schedule as specified in the arms.

  • Ocrelizumab will be administered per schedule as specified in the arms.

    Also known as: RO4964913, Ocrevus

  • DrugPlacebo

    Placebo will be administered per schedule as specified in the arms.

06

What researchers measure

Primary outcomes

  1. Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)

    Time from randomization to the first occurrence of cCDP12 according to at least one of the following 3 criteria: 1. 12-week confirmed disability progression (CDP12) 2. 12-week confirmed increase in Timed 25-Foot Walk Test (T25FWT) or 3. 12-week confirmed increase in 9-Hole Peg Test (9-HPT) The EDSS is a disability scale is based on a standard neurological examination that ranges in 0.5-point steps from 0 (normal) - 10 (death). T25FWT=time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. In 9-HPT, participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. The shorter time it takes to complete the task indicates a better outcome.

    Time frame: Up to approximately 110 weeks

Secondary outcomes

  1. Time From Randomization to the First Occurrence of 24-Week Confirmed ≥4-Point Decrease (Worsening) in Symbol Digit Modalities Test (SDMT)

    The SDMT is a performance measure of processing speed that is widely used to assess cognitive function in response to treatment. It's brief, easy to administer, and involves a simple substitution task that healthy children and adults can easily perform. Using a reference key, the participant has 90 seconds to pair specific numbers with given geometric figures. The total SDMT score is the total number of correct responses and ranges from 0 to 110, with a higher score indicating a higher level of processing speed. A four-point change from baseline is typically considered clinically meaningful.

    Time frame: Up to approximately 110 weeks

  2. Time to Onset of 24-Week cCDP (cCDP24)

    Time frame: Up to approximately 110 weeks

  3. Time to Onset of 12-Week Confirmed Disability Progression CDP (CDP12)

    Time frame: Up to approximately 110 weeks

  4. Time to Onset of 24-Week CDP (CDP24)

    Time frame: Up to approximately 110 weeks

  5. Time to ≥ 20% Increase in 12-week Confirmed Timed 25-Foot Walk Test (T25FWT)

    The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.

    Time frame: Up to approximately 110 weeks

  6. Time to ≥ 20% Increase in 24-week Confirmed T25FWT

    The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.

    Time frame: Up to approximately 110 weeks

  7. Time to ≥ 20% Increase in 12-week Confirmed 9-Hole Peg Test (9-HPT)

    Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

    Time frame: Up to approximately 110 weeks

  8. Time to ≥ 20% Increase in 24-week Confirmed 9-HPT

    Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, \& then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

    Time frame: Up to approximately 110 weeks

  9. Change From Baseline in Total Brain Volume

    Time frame: Up to approximately 110 weeks

  10. Plasma 2-arachidonoylglycerol (2-AG) Levels

    Time frame: Up to approximately 110 weeks

  11. Change From Baseline in Plasma 2-AG Levels

    Time frame: Up to approximately 110 weeks

  12. Number of Participants With Adverse events (AEs)

    Time frame: Up to 5 years

  13. Number of Participants With Treatment Discontinuations due to AEs

    Time frame: Up to 5 years

  14. Proportion of Participants With Suicidal Ideation or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.

    Time frame: Up to 5 years

  15. Plasma Concentrations of RO7268489 and Its Metabolite(s)

    Time frame: Up to 5 years

07

Study locations

114 of 114 sites recruiting

Showing the first 100 of 114 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 15, 2025
StartActual
Mar 10, 2026
Primary completionEst.
May 30, 2028
CompletionEst.
May 30, 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Brazil
Show 6 added (2 Germany, 2 Hungary, 1 Brazil, 1 Turkey (Türkiye))
  • Centro de Pesquisas Clinicas - CPCLIN · São Paulo, Brazil
  • Universitaetsklinikum Frankfurt Goethe-Universitaet · Frankfurt am Main, Germany
  • Universitaetsklinikum Bonn AoeR · Bonn, Germany
  • Semmelweis Egyetem · Budapest, Hungary
  • Somogy Varmegyei Kaposi Mor Oktato Korhaz · Kaposvár, Hungary
  • Izmir Katip Celebi Universitesi Ataturk Research and Training Hospital · Izmir, Turkey (Türkiye)
Oct 7, 2026
Eligibility
1 inclusion criterion added; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedDocumented evidence of disability progression independent of relapse activity over the 2 years before the screening visit
Exclusion criteria
  • EditedHistory of alcohol or other drug abuse (substance use disorder) based on Diagnostic and Statistical Manual for Mental Disorders, in the opinion of the investigatorfifth edition (DSM-5) criteria, within 5 years prior to screening
  • EditedInability to complete ana magnetic resonance imaging (MRI)
Oct 7, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTime to ≥ 20% Increase in 24-week Confirmed 9-HPT: how it is measured was reworded
Oct 7, 2026
Contact
Study contact changed: g•••@gene.com · •••6728→g•••@gene.com · •••6728; person changed (no phone or email listed). See the current contact
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    6 sites added — first site in Brazil
    Show 6 added (2 Germany, 2 Hungary, 1 Brazil, 1 Turkey (Türkiye))
    • Centro de Pesquisas Clinicas - CPCLIN · São Paulo, Brazil
    • Universitaetsklinikum Frankfurt Goethe-Universitaet · Frankfurt am Main, Germany
    • Universitaetsklinikum Bonn AoeR · Bonn, Germany
    • Semmelweis Egyetem · Budapest, Hungary
    • Somogy Varmegyei Kaposi Mor Oktato Korhaz · Kaposvár, Hungary
    • Izmir Katip Celebi Universitesi Ataturk Research and Training Hospital · Izmir, Turkey (Türkiye)
    Eligibility 1 inclusion criterion added; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedDocumented evidence of disability progression independent of relapse activity over the 2 years before the screening visit
    Exclusion criteria
    • EditedHistory of alcohol or other drug abuse (substance use disorder) based on Diagnostic and Statistical Manual for Mental Disorders, in the opinion of the investigatorfifth edition (DSM-5) criteria, within 5 years prior to screening
    • EditedInability to complete ana magnetic resonance imaging (MRI)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTime to ≥ 20% Increase in 24-week Confirmed 9-HPT: how it is measured was reworded
    Contact Study contact changed: g•••@gene.com · •••6728→g•••@gene.com · •••6728; person changed (no phone or email listed). See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07282574
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Mar 10, 2026
Primary completion
May 30, 2028 (estimated)
Completion
May 30, 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

Reference Study ID Number: BP46016 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion